Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia signs new clinical account in France

AIFORIAAnalyst Comment19.05.2025, 13.45
Antti Luiro, Frans-Mikael Rostedt
Discuss

Translation: Original published in Finnish on 5/19/2025 at 2:14 pm EEST.

Nantes University Hospital will deploy Aiforia's software in clinical diagnostics. The value of the two-year agreement was not communicated in the release. Nantes is the sixth largest university hospital in France, and its catchment area has a population of 800,000. Based on this and the value of Aiforia's previous customer relationships, we estimate that the customer relationship corresponds to less than EUR 100,000 in annual revenue in the initial phase. According to the release, the agreement only includes a part of the company's image recognition models, so the customer relationship has potential for expansion already with the company's current product portfolio. 

This is Aiforia's second clinical segment agreement in France, where the Assistance Publique - Hôpitaux de Paris (AP-HP hospital group) adopted Aiforia in 2024. Although the now-announced agreement is relatively small in size, it still sends a good message about the company's market position and the pace at which the market is forming. The release supports our forecasts of strong revenue growth but does not create pressure for forecast changes.

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures23.04.2025

202425e26e
Revenue2.94.77.6
growth-%18.9 %65.7 %60.0 %
EBIT (adj.)-12.2-11.9-12.0
EBIT-% (adj.)-427.8 %-252.9 %-158.1 %
EPS (adj.)-0.41-0.37-0.38
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Updated shareholder list. Laakkonen, Syrjälä, and Pyysing have bought more shares. https://investors.aiforia.com/fi/sijoittajat/osaketieto/osakkeenomi...
6 hours ago
by TO
14
Good comment! Though I don’t think the speakers are paid separately for this
10/29/2026, 7:52 AM
by Bullbear
0
https://www.fortunebusinessinsights.com/computational-pathology-market-119487 Over there, you can take a look at the latest estimates for the...
10/29/2026, 7:29 AM
by Salvelinus
6
DeciBio is a strategy consulting and market intelligence firm. Maloney is a partner there. My baseline assumption is that someone of his caliber...
10/29/2026, 7:27 AM
by Vino Pino
7
First, Aiforia puts investors’ money into Decibio’s reports and services, and then Decibio comes to talk up positive things in an investor webinar...
10/28/2026, 6:16 PM
by Bullbear
0
Oh, and the CEO is in Singapore November 1–3 for the ASDP 2026 event with their team, in case anyone didn’t know.
10/28/2026, 7:36 AM
by Salvelinus
7
We haven’t been forgotten. Investor webinar on 17/11/26. Looks like Maloney is involved too. “Live subtitles as well as AI-generated simultaneous...
10/28/2026, 7:34 AM
by Vino Pino
13